Functional neuroimaging in schizophrenia: diagnosis and drug discovery - PubMed (original) (raw)
Review
Functional neuroimaging in schizophrenia: diagnosis and drug discovery
Philip McGuire et al. Trends Pharmacol Sci. 2008 Feb.
Abstract
Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.
Similar articles
- [Background and findings of neuroimaging in schizophrenia: an update].
Cuevas-Esteban J, Campayo A, Gutiérrez-Galve L, Gracia-García P, López-Antón R. Cuevas-Esteban J, et al. Rev Neurol. 2011 Jan 1;52(1):27-36. Rev Neurol. 2011. PMID: 21246491 Review. Spanish. - [Neuroimaging in schizophrenia].
Lanzenberger R, Kasper S. Lanzenberger R, et al. Fortschr Neurol Psychiatr. 2005 Nov;73 Suppl 1:S51-9. doi: 10.1055/s-2005-915581. Fortschr Neurol Psychiatr. 2005. PMID: 16270245 Review. German. - Chemical and physiologic brain imaging in schizophrenia.
McClure RJ, Keshavan MS, Pettegrew JW. McClure RJ, et al. Psychiatr Clin North Am. 1998 Mar;21(1):93-122. doi: 10.1016/s0193-953x(05)70363-4. Psychiatr Clin North Am. 1998. PMID: 9551493 Review. - Neuroimaging in psychiatry: An update.
Abou-Saleh MT. Abou-Saleh MT. J Psychosom Res. 2006 Sep;61(3):289-93. doi: 10.1016/j.jpsychores.2006.06.012. J Psychosom Res. 2006. PMID: 16938503 Review. - Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Howes OD, et al. Curr Pharm Des. 2009;15(22):2550-9. doi: 10.2174/138161209788957528. Curr Pharm Des. 2009. PMID: 19689327 Free PMC article. Review.
Cited by
- Abnormal regional homogeneity as potential imaging biomarker for psychosis risk syndrome: a resting-state fMRI study and support vector machine analysis.
Wang S, Wang G, Lv H, Wu R, Zhao J, Guo W. Wang S, et al. Sci Rep. 2016 Jun 8;6:27619. doi: 10.1038/srep27619. Sci Rep. 2016. PMID: 27272341 Free PMC article. - Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects.
Rampino A, Marakhovskaia A, Soares-Silva T, Torretta S, Veneziani F, Beaulieu JM. Rampino A, et al. Front Psychiatry. 2019 Jan 9;9:702. doi: 10.3389/fpsyt.2018.00702. eCollection 2018. Front Psychiatry. 2019. PMID: 30687136 Free PMC article. Review. - Mapping the landscape: a bibliometric analysis of resting-state fMRI research on schizophrenia over the past 25 years.
Fu L, Aximu R, Zhao G, Chen Y, Sun Z, Xue H, Wang S, Zhang N, Zhang Z, Lei M, Zhai Y, Xu J, Sun J, Ma J, Liu F. Fu L, et al. Schizophrenia (Heidelb). 2024 Mar 15;10(1):35. doi: 10.1038/s41537-024-00456-2. Schizophrenia (Heidelb). 2024. PMID: 38490990 Free PMC article. - Psychosis, vulnerability, and the moral significance of biomedical innovation in psychiatry. Why ethicists should join efforts.
Corsico P. Corsico P. Med Health Care Philos. 2020 Jun;23(2):269-279. doi: 10.1007/s11019-019-09932-4. Med Health Care Philos. 2020. PMID: 31773383 Free PMC article. - Using NMR approaches to drive the search for new CNS therapeutics.
Borsook D, Becerra L. Borsook D, et al. Curr Opin Investig Drugs. 2010 Jul;11(7):771-8. Curr Opin Investig Drugs. 2010. PMID: 20571972 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical